Imeglimin Exerts Anti-Tumor Activity in Multiple Myeloma Through Affecting Energy Metabolism and Downregulating IL-16 Expression - PubMed
8 hours ago
- #IL-16
- #Imeglimin
- #Multiple Myeloma
- Imeglimin (IME) shows anti-tumor activity in multiple myeloma (MM) by affecting energy metabolism and downregulating IL-16 expression.
- IME inhibits MM cell proliferation and tumor growth in xenograft models, inducing G1/G0 cell cycle arrest.
- IME suppresses oxidative phosphorylation and promotes glycolysis in MM cells.
- IL-16 mRNA expression is downregulated, and cytokine-cytokine receptor interaction pathways are altered by IME treatment.
- The anti-MM effect of IME is partly due to increased lactate production and decreased IL-16 expression.
- Single-cell transcriptomic data highlight IL-16's role in the bone marrow microenvironment of MM.
- IME may offer a novel therapeutic approach for MM by targeting IL-16 and energy metabolism.